Exosome miR-155-5p Derived from Lung Cancer Hcc827 Promotes Macrophage Activation and Lung Cancer Progression

This stud intends to assess whether exosome miR-155-5p derived from human non-small cell lung cancer cells (Hcc827) activates macrophages in lung cancer. Lung cancer Hcc827 cells were assigned into control group and expeirmental group (cultured with macrophages, THP-1 activated by exosome miR-155-5P derived from Hcc827) followed by analysis of macrophage markers inducible nitric oxide synthase (INOS), recombinant human CD163 (CD163), matrix metallopeptidase 9 (MMP9), matrix metallopeptidase 2 (MMP2), and E-cadherin by real-time fluorescent quantitative PCR (RFQ-PCR), IL-10, IL-6 and IL-8 levels by chemiluminescence, cell invasion by Transwell assay and related protein expression by Western blot. miR-155-5p treatment significantly reduced INOS and TNF-β expressions and increased CD163, TNF-α, IL-8, IL-6 and IL-10 expressions along with enhanced cell invasion. In addition, MMP9 and MMP2 expressions in experimental group were significantly increased and E-cdherin was reduced. In conclusion, exosome miR-155-5p derived from lung cancer Hcc827 cells activates macrophages and enhanced lung cancer cell invasion.

Download Full-text

Evaluation of non-small cell lung cancer treatment strategies in a region of China with low-risk for COVID-19

10.21203/rs.3.rs-78352/v2 ◽

2020 ◽

Author(s):

Minhao Yu ◽

Yalin Cheng

Keyword(s):

Lung Cancer ◽

Cancer Progression ◽

Late Stage ◽

Early Stage ◽

Treatment Strategies ◽

Small Cell ◽

Low Risk ◽

Control Group ◽

Small Cell Lung ◽

Experimental Group

Abstract Purpose This study analyzed the morbidity and mortality associated with non-small cell lung cancer (NSCLC) and evaluated treatment strategies for it in a low-risk area of COVID-19 in China. Materials and methods: We selected patients admitted to Sichuan Science City Hospital from September 2019 to February 2020 and divided them into experimental and control groups. The treatment strategy was evaluated by patients’ prognosis. Results: 9,010 patients were hospitalized. The total morbidity was 0.699%, of which 0.504% was observed in the control group and 0.991% in the experimental group (P=0.024). The total mortality was 0.999/103, of which 0.630/103 was observed in the control group and 1.413/103 in the experimental group (P=0.322). Therapy discontinuation and cancer progression in the experimental group were significantly higher than the control group (P＜0.001, P=0.007). The treatment methods and prognosis were not significantly different for early-stage patients between the two groups. Late-stage patients in the experimental group experienced significantly lower percentages of non-surgical treatments (P＜0.001), higher percentages of discontinued therapies (P＜0.001), lower percentages for prognosis of wellness (P＜0.001), and higher percentages of cancer progression (P＜0.001) than the control group. Conclusion: NSCLC exhibited significantly higher morbidities during the COVID-19 pandemic. The mortality in the experimental group was slightly higher than the control group, while the difference in cancer progression was significant. It is feasible to perform surgery for early-stage NSCLC patients, and treatment should not be suspended for late-stage patients in regions with low-risk for COVID-19 infection.

Download Full-text

Downregulation of Cyclophilin A by siRNA diminishes non-small cell lung cancer cell growth and metastasis via the regulation of matrix metallopeptidase 9

BMC Cancer ◽

10.1186/1471-2407-12-442 ◽

2012 ◽

Vol 12 (1) ◽

Cited By ~ 22

Author(s):

Zhe Qian ◽

Xiaoting Zhao ◽

Mei Jiang ◽

Wenyun Jia ◽

Chunyan Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Cell Growth ◽

Small Cell Lung Cancer ◽

Cyclophilin A ◽

Small Cell ◽

Lung Cancer Cell ◽

Small Cell Lung ◽

Cancer Cell Growth ◽

Matrix Metallopeptidase ◽

Matrix Metallopeptidase 9

Download Full-text

The morbidity and mortality of non-small cell lung cancer in low risk areas of the COVID-19

10.21203/rs.3.rs-78352/v1 ◽

2020 ◽

Author(s):

Minhao Yu ◽

Yalin Cheng

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Progression ◽

Cell Lung Cancer ◽

Small Cell ◽

Low Risk ◽

Control Group ◽

Small Cell Lung ◽

Risk Areas ◽

Experimental Group

Abstract Objective: To analyze the morbidity and mortality of non-small cell lung cancer and evaluate treatment strategies for non-small cell lung cancer patients in low-risk areas of the COVID-19.Materials and methods: We selected patients in the hospital in Sichuan Science City Hospital from September 2019 to February 2020 as research subjects and divided them into experimental and control groups. The evaluation of treatment strategy was based on morbidity and mortality.Results: There were 9010 patients hospitalized. The total morbidity was 0.699%, which was 0.504% in the control group and 0.991% in the experimental group (P=0.024). The total mortality was 0.887 /103, which was 0.840/103 in the control group (4/4764) and 0.942/103 in the experimental group (P=0.998). The patients discontinued therapy or follow-up and cancer progression in the experimental group was significantly higher than that in the control group (P＜0.001, =0.007). Most of the discontinued and progressive cancer patients were elderly and in late stage.Conclusion: The morbidity of NSCLC during the COVID-19 pandemic was significantly high. The mortality in the experimental group was slightly higher than that in the control group, while the difference in cancer progression was significant. It is practicable to perform surgery for early-stage NSCLC patients and undesirable to suspend treatment for late-stage patients in low-risk areas.

Download Full-text

Mitochondria-Targeted Antioxidants MitoQ and MitoTEMPO Do Not Influence BRAF-Driven Malignant Melanoma and KRAS-Driven Lung Cancer Progression in Mice

Antioxidants ◽

10.3390/antiox10020163 ◽

2021 ◽

Vol 10 (2) ◽

pp. 163

Author(s):

Kristell Le Gal ◽

Clotilde Wiel ◽

Mohamed X. Ibrahim ◽

Marcus Henricsson ◽

Volkan I. Sayin ◽

...

Keyword(s):

Lung Cancer ◽

Malignant Melanoma ◽

Cancer Cells ◽

Cancer Progression ◽

Nuclear Dna ◽

Human Melanoma ◽

Oxygen Species ◽

Lung Cancer Cell ◽

Primary Tumors ◽

Anti Cancer

Cancer cells produce high levels of mitochondria-associated reactive oxygen species (ROS) that can damage macromolecules, but also promote cell signaling and proliferation. Therefore, mitochondria-targeted antioxidants have been suggested to be useful in anti-cancer therapy, but no studies have convincingly addressed this question. Here, we administered the mitochondria-targeted antioxidants MitoQ and MitoTEMPO to mice with BRAF-induced malignant melanoma and KRAS-induced lung cancer, and found that these compounds had no impact on the number of primary tumors and metastases; and did not influence mitochondrial and nuclear DNA damage levels. Moreover, MitoQ and MitoTEMPO did not influence proliferation of human melanoma and lung cancer cell lines. MitoQ and its control substance dTPP, but not MitoTEMPO, increased glycolytic rates and reduced respiration in melanoma cells; whereas only dTPP produced this effect in lung cancer cells. Our results do not support the use of mitochondria-targeted antioxidants for anti-cancer monotherapy, at least not in malignant melanoma and lung cancer.

Download Full-text